Loading...
XNAS
CORT
Market cap9.06bUSD
Dec 05, Last price  
86.11USD
1D
1.71%
1Q
24.14%
Jan 2017
1,086.02%
IPO
617.54%
Name

Corcept Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CORT chart
P/E
64.82
P/S
13.42
EPS
1.33
Div Yield, %
—
Shrs. gr., 5y
-1.53%
Rev. gr., 5y
17.11%
Revenues
675m
+39.94%
0294,000482,000209,00029,000003,307,00010,357,00026,551,00050,286,00081,321,000159,201,000251,247,000306,486,000353,874,000365,978,000401,858,000482,375,000675,040,000
Net income
140m
+31.65%
-20,093,000-24,873,000-11,573,000-20,061,000-20,166,000-25,966,000-32,354,000-38,048,000-46,011,000-31,383,000-6,408,0008,140,000129,122,00075,410,00094,181,000106,011,000112,512,000101,418,000106,140,000139,733,000
CFO
198m
+55.91%
-17,234,000-23,238,000-10,964,000-18,362,000-17,968,000-22,285,000-27,400,000-36,020,000-37,058,000-27,376,0003,130,00018,391,00060,935,000115,665,000136,117,000151,970,000167,892,000120,323,000127,039,000198,067,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
URL
https://www.corcept.com/
IPO date
Apr 15, 2004
Employees
299
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT